Panel Spotlight: "How to Catch and Treat Cancer Early"

Date: DAY ONE: May 10, 2022
Time: 11:00 AM


Sequential liquid biopsies are transforming cancer care and management (Turner: “The future of liquid biopsy” The Lancet Oncology, 2020). However, the challenges of implementing liquid biopsies as a tool for early detection were elegantly described in Swanton’s Nature Reviews of Oncology, 2018: “Early stage NSCLC – challenges to implementing ctDNA-based screening and MRD detection” This panel will update current progress on “the holy grail”: an annual affordable test to detect cancer at its earliest stages as part of an annual physical examination. The next obvious challenge will be administration of therapies to treat (and hopefully destroy) malignant subclones before the cancer is detected by current conventional methods.


Moderated By:
Jeff Bockman, PhD,
EVP, Commercial BioConsulting and Head of Oncology

Jeff leads the Oncology and Virology Practices at Lumanity. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at Cello Health BioConsulting, now Lumanity. He often speaks at conferences on scientific and commercial issues in cancer, especially immuno-oncology.

arrow FULL BIO


• Peter Bach, MD, CMO, Delfi Diagnostics

• Kapil Dhingra, MB, BS, Managing Member, KAPital Consulting LLC

• Colin Hill, CEO and Co-Founder, GNS Healthcare

• Christoph Lengauer, PhD, MBA, Partner, Third Rock Ventures; Thrive/Exact Sciences

• John Sninsky, UCSF Clinical & Translational Science Institute, Catalyst Advisor, Diagnostics, CSO, CareDx

Thank You to Our 2022 Sponsors!
Platinum Partnering Sponsors
Gold Sponsor
Silver Sponsor
Bronze Sponsors
Promotional Partners

Lumanity was formed to bring together diverse perspectives and unique clinical, scientific, and functional expertise to uncover innovative, yet pragmatic approaches to address the complex set of challenges on the path to market.

We apply incisive thinking and decisive action to cut through complex situations and deliver transformative outcomes to accelerate and optimize access to medical advances. With deep experience in scientific, medical, commercial, and regulatory affairs, Lumanity transforms data and information into real-world insights and evidence that powers successful development and commercialization and empowers patients, providers, payers, and regulators to take timely and decisive action.

We partner with life science companies around the world to: define the opportunity and value proposition and generate the evidence needed to demonstrate the value of their products and bring them to patients at a price reflective of that value; translate science and data into compelling product narratives that are relevant to stakeholders around the world; and enable commercial decisions that will position these products for success in the market. We have been illuminating new possibilities and driving impact for global clients for over 30 years.

There is no “one size fits all” approach to creating the right development and commercial strategy for your asset. Defining the opportunity, differentiating your asset, and adding incremental value beyond standard of care is vital and has become more challenging in an increasingly complex and competitive context. Lumanity does more than guide your commercial strategy; we uncover real-world insights that go beyond the ‘what’ to understand the ‘why’, providing pharmaceutical and biotech companies with robust development and commercial strategies they can be confident in across the lifecycle: from innovation through development to commercialization and beyond.

Cancer Progress
25-B Hanover Road, Suite 320
Florham Park, NJ 07932
Eileen Tuma, Conference Organizer |

linkedin twitter